Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Development of Entry-Targeted Oncolytic Measles Viruses.

Mühlebach MD, Cattaneo R.

Methods Mol Biol. 2020;2058:51-75. doi: 10.1007/978-1-4939-9794-7_4.

PMID:
31486031
2.

Chronic E-Cigarette Use Increases Neutrophil Elastase and Matrix Metalloprotease Levels in the Lung.

Ghosh A, Coakley RD, Ghio AJ, Muhlebach MS, Esther CR Jr, Alexis NE, Tarran R.

Am J Respir Crit Care Med. 2019 Aug 7. doi: 10.1164/rccm.201903-0615OC. [Epub ahead of print]

PMID:
31390877
3.

Highlights from the 2018 North American cystic fibrosis conference.

Martiniano SL, Daines CL, Dellon EP, Esther CR Jr, Muhlebach MS, Ong T, Rabinowitz EC, Toprak D, Zemanick ET.

Pediatr Pulmonol. 2019 Jul;54(7):941-948. doi: 10.1002/ppul.24356. Epub 2019 May 15. Review.

PMID:
31091021
4.

Cystic fibrosis program characteristics associated with adoption of 2013 infection prevention and control recommendations.

Stoudemire W, Jiang X, Zhou JJ, Maykowski P, Kosorok MR, Muhlebach MS, Saiman L.

Am J Infect Control. 2019 Sep;47(9):1090-1095. doi: 10.1016/j.ajic.2019.03.015. Epub 2019 Apr 27.

PMID:
31036402
5.

Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis.

Esther CR Jr, Muhlebach MS, Ehre C, Hill DB, Wolfgang MC, Kesimer M, Ramsey KA, Markovetz MR, Garbarine IC, Forest MG, Seim I, Zorn B, Morrison CB, Delion MF, Thelin WR, Villalon D, Sabater JR, Turkovic L, Ranganathan S, Stick SM, Boucher RC.

Sci Transl Med. 2019 Apr 3;11(486). pii: eaav3488. doi: 10.1126/scitranslmed.aav3488.

6.

Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis.

Sherrard LJ, Einarsson GG, Johnston E, O'Neill K, McIlreavey L, McGrath SJ, Gilpin DF, Downey DG, Reid A, McElvaney NG, Boucher RC, Muhlebach MS, Elborn JS, Tunney MM.

J Cyst Fibros. 2019 Mar 21. pii: S1569-1993(19)30052-9. doi: 10.1016/j.jcf.2019.02.012. [Epub ahead of print]

PMID:
30905581
7.

Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma.

Rajaraman S, Canjuga D, Ghosh M, Codrea MC, Sieger R, Wedekink F, Tatagiba M, Koch M, Lauer UM, Nahnsen S, Rammensee HG, Mühlebach MD, Stevanovic S, Tabatabai G.

Mol Ther Oncolytics. 2018 Dec 31;12:147-161. doi: 10.1016/j.omto.2018.12.010. eCollection 2019 Mar 29.

8.

A Measles Virus-Based Vaccine Candidate Mediates Protection against Zika Virus in an Allogeneic Mouse Pregnancy Model.

Nürnberger C, Bodmer BS, Fiedler AH, Gabriel G, Mühlebach MD.

J Virol. 2019 Jan 17;93(3). pii: e01485-18. doi: 10.1128/JVI.01485-18. Print 2019 Feb 1.

9.

Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from cystic fibrosis (CF) and non-CF patients.

Sherrard LJ, Schaible B, Graham KA, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, Muhlebach MS, Gilpin DF, Schneiders T, Stuart Elborn J, Tunney MM.

J Antimicrob Chemother. 2018 Nov 1;73(11):3218. doi: 10.1093/jac/dky313. No abstract available.

PMID:
30351435
10.

Biology and management of methicillin resistant Staphylococcus aureus in cystic fibrosis.

Akil N, Muhlebach MS.

Pediatr Pulmonol. 2018 Nov;53(S3):S64-S74. doi: 10.1002/ppul.24139. Epub 2018 Aug 2. Review.

PMID:
30073802
11.

Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.

Lo DK, Muhlebach MS, Smyth AR.

Cochrane Database Syst Rev. 2018 Jul 21;7:CD009650. doi: 10.1002/14651858.CD009650.pub4. Review.

12.

Tracheostomy in children: Epidemiology and clinical outcomes.

Sanders CD, Guimbellot JS, Muhlebach MS, Lin FC, Gilligan P, Esther CR Jr.

Pediatr Pulmonol. 2018 Sep;53(9):1269-1275. doi: 10.1002/ppul.24071. Epub 2018 Jul 3.

PMID:
29968973
13.

Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study.

Muhlebach MS, Hatch JE, Einarsson GG, McGrath SJ, Gilipin DF, Lavelle G, Mirkovic B, Murray MA, McNally P, Gotman N, Davis Thomas S, Wolfgang MC, Gilligan PH, McElvaney NG, Elborn JS, Boucher RC, Tunney MM.

Eur Respir J. 2018 Jul 11;52(1). pii: 1800242. doi: 10.1183/13993003.00242-2018. Print 2018 Jul.

14.
15.

Modular MLV-VLPs co-displaying ovalbumin peptides and GM-CSF effectively induce expansion of CD11b+ APC and antigen-specific T cell responses in vitro.

Gogesch P, Schülke S, Scheurer S, Mühlebach MD, Waibler Z.

Mol Immunol. 2018 Sep;101:19-28. doi: 10.1016/j.molimm.2018.05.017. Epub 2018 May 28.

PMID:
29852456
16.

Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations.

Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP.

Diagn Microbiol Infect Dis. 2018 Jul;91(3):294-297. doi: 10.1016/j.diagmicrobio.2018.01.020. Epub 2018 Feb 24.

PMID:
29661528
17.

Highlights from the 2017 North American Cystic Fibrosis Conference.

Martiniano SL, Toprak D, Ong T, Zemanick ET, Daines CL, Muhlebach MS, Esther CR Jr, Dellon EP.

Pediatr Pulmonol. 2018 Jul;53(7):979-986. doi: 10.1002/ppul.24000. Epub 2018 Apr 16. Review.

PMID:
29660839
18.

Surveying Cystic Fibrosis Care Centers to Assess Adoption of Infection Prevention and Control Recommendations.

Saiman L, Zhou JJ, Jiang X, Kosorok MR, Muhlebach MS.

Infect Control Hosp Epidemiol. 2018 Jun;39(6):647-651. doi: 10.1017/ice.2018.72. Epub 2018 Apr 15.

PMID:
29655374
19.

Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children.

Muhlebach MS, Zorn BT, Esther CR, Hatch JE, Murray CP, Turkovic L, Ranganathan SC, Boucher RC, Stick SM, Wolfgang MC.

PLoS Pathog. 2018 Jan 18;14(1):e1006798. doi: 10.1371/journal.ppat.1006798. eCollection 2018 Jan.

20.

Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles.

Hutzler S, Erbar S, Jabulowsky RA, Hanauer JRH, Schnotz JH, Beissert T, Bodmer BS, Eberle R, Boller K, Klamp T, Sahin U, Mühlebach MD.

Sci Rep. 2017 Dec 4;7(1):16892. doi: 10.1038/s41598-017-16928-8.

21.

Virotherapy Research in Germany: From Engineering to Translation.

Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM.

Hum Gene Ther. 2017 Oct;28(10):800-819. doi: 10.1089/hum.2017.138. Review.

PMID:
28870120
22.

Methicillin-resistant Staphylococcus aureus in cystic fibrosis: how should it be managed?

Muhlebach MS.

Curr Opin Pulm Med. 2017 Nov;23(6):544-550. doi: 10.1097/MCP.0000000000000422. Review.

PMID:
28796008
23.

Vaccine platform recombinant measles virus.

Mühlebach MD.

Virus Genes. 2017 Oct;53(5):733-740. doi: 10.1007/s11262-017-1486-3. Epub 2017 Jul 14. Review.

PMID:
28710608
24.

Highlights from the 2016 North American Cystic Fibrosis Conference.

Zemanick ET, Daines CL, Dellon EP, Esther CR Jr, Kinghorn B, Ong T, Muhlebach MS.

Pediatr Pulmonol. 2017 Aug;52(8):1103-1110. doi: 10.1002/ppul.23707. Epub 2017 Jul 11. Review.

25.

Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective.

Kleinlützum D, Hanauer JDS, Muik A, Hanschmann KM, Kays SK, Ayala-Breton C, Peng KW, Mühlebach MD, Abel T, Buchholz CJ.

Front Oncol. 2017 Jun 26;7:127. doi: 10.3389/fonc.2017.00127. eCollection 2017.

26.

Development of Recombinant Measles Virus-Based Vaccines.

Mühlebach MD, Hutzler S.

Methods Mol Biol. 2017;1581:151-168. doi: 10.1007/978-1-4939-6869-5_9.

PMID:
28374248
27.

Biomarkers for cystic fibrosis drug development.

Muhlebach MS, Clancy JP, Heltshe SL, Ziady A, Kelley T, Accurso F, Pilewski J, Mayer-Hamblett N, Joseloff E, Sagel SD.

J Cyst Fibros. 2016 Nov;15(6):714-723. doi: 10.1016/j.jcf.2016.10.009. Epub 2016 Oct 27. Review.

28.

Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial.

Muhlebach MS, Beckett V, Popowitch E, Miller MB, Baines A, Mayer-Hamblett N, Zemanick ET, Hoover WC, VanDalfsen JM, Campbell P, Goss CH; STAR-too study team.

Thorax. 2017 Apr;72(4):318-326. doi: 10.1136/thoraxjnl-2016-208949. Epub 2016 Nov 15.

29.

Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis.

Esther CR Jr, Turkovic L, Rosenow T, Muhlebach MS, Boucher RC, Ranganathan S, Stick SM; AREST CF.

Eur Respir J. 2016 Dec;48(6):1612-1621. doi: 10.1183/13993003.00524-2016. Epub 2016 Nov 11.

30.

Progression of Polysomnographic Abnormalities in Mucolipidosis II (I-Cell Disease).

Wooten WI 3rd, Muhlebach MS, Muenzer J, Loughlin CE, Vaughn BV.

J Clin Sleep Med. 2016 Dec 15;12(12):1695-1696. doi: 10.5664/jcsm.6362.

31.

Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.

Monogue ML, Pettit RS, Muhlebach M, Cies JJ, Nicolau DP, Kuti JL.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6578-6584. doi: 10.1128/AAC.01566-16. Print 2016 Nov.

32.

APOBEC4 Enhances the Replication of HIV-1.

Marino D, Perković M, Hain A, Jaguva Vasudevan AA, Hofmann H, Hanschmann KM, Mühlebach MD, Schumann GG, König R, Cichutek K, Häussinger D, Münk C.

PLoS One. 2016 Jun 1;11(6):e0155422. doi: 10.1371/journal.pone.0155422. eCollection 2016.

33.

Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors.

Hanauer JR, Gottschlich L, Riehl D, Rusch T, Koch V, Friedrich K, Hutzler S, Prüfer S, Friedel T, Hanschmann KM, Münch RC, Jost C, Plückthun A, Cichutek K, Buchholz CJ, Mühlebach MD.

Mol Ther Oncolytics. 2016 Feb 24;3:16003. doi: 10.1038/mto.2016.3. eCollection 2016.

34.

Highlights from the 2015 North American Cystic Fibrosis Conference.

Zemanick ET, Ong T, Daines CL, Dellon EP, Muhlebach MS, Esther CR Jr.

Pediatr Pulmonol. 2016 Jun;51(6):650-7. doi: 10.1002/ppul.23441. Epub 2016 Apr 13.

35.

Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota.

Sherrard LJ, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, Muhlebach MS, Gilpin DF, Elborn JS, Tunney MM.

Int J Antimicrob Agents. 2016 Feb;47(2):140-5. doi: 10.1016/j.ijantimicag.2015.12.004. Epub 2015 Dec 29.

36.

Suppressing active replication of a live attenuated simian immunodeficiency virus vaccine does not abrogate protection from challenge.

Gabriel B, Fiebig U, Hohn O, Plesker R, Coulibaly C, Cichutek K, Mühlebach MD, Bannert N, Kurth R, Norley S.

Virology. 2016 Feb;489:1-11. doi: 10.1016/j.virol.2015.11.030. Epub 2015 Dec 11.

37.

Lessons learned from metabolomics in cystic fibrosis.

Muhlebach MS, Sha W.

Mol Cell Pediatr. 2015 Dec;2(1):9. doi: 10.1186/s40348-015-0020-8. Epub 2015 Oct 20.

38.

Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis.

Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP, Kuti JL.

J Antimicrob Chemother. 2016 Jan;71(1):189-95. doi: 10.1093/jac/dkv289. Epub 2015 Sep 27.

PMID:
26416780
39.

A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.

Malczyk AH, Kupke A, Prüfer S, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, Eldin HS, Schmidt J, Vergara-Alert J, Süzer Y, Seifried J, Hanschmann KM, Kalinke U, Herold S, Sahin U, Cichutek K, Waibler Z, Eickmann M, Becker S, Mühlebach MD.

J Virol. 2015 Nov;89(22):11654-67. doi: 10.1128/JVI.01815-15. Epub 2015 Sep 9.

40.

Outcomes and Treatment of Chronic Methicillin-Resistant Staphylococcus aureus Differs by Staphylococcal Cassette Chromosome mec (SCCmec) Type in Children With Cystic Fibrosis.

Heltshe SL, Saiman L, Popowitch EB, Miller MB, Kloster M, Thompson V, Ferkol TW, Hoover WC, Schechter MS, Muhlebach MS.

J Pediatric Infect Dis Soc. 2015 Sep;4(3):225-31. doi: 10.1093/jpids/piu048. Epub 2014 Jun 9.

41.

The Role of Short-Chain Fatty Acids, Produced by Anaerobic Bacteria, in the Cystic Fibrosis Airway.

Mirković B, Murray MA, Lavelle GM, Molloy K, Azim AA, Gunaratnam C, Healy F, Slattery D, McNally P, Hatch J, Wolfgang M, Tunney MM, Muhlebach MS, Devery R, Greene CM, McElvaney NG.

Am J Respir Crit Care Med. 2015 Dec 1;192(11):1314-24. doi: 10.1164/rccm.201505-0943OC.

42.

Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response.

Uhlig KM, Schülke S, Scheuplein VA, Malczyk AH, Reusch J, Kugelmann S, Muth A, Koch V, Hutzler S, Bodmer BS, Schambach A, Buchholz CJ, Waibler Z, Scheurer S, Mühlebach MD.

J Virol. 2015 Sep;89(17):9044-60. doi: 10.1128/JVI.00844-15. Epub 2015 Jun 17.

43.

Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.

Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP.

Diagn Microbiol Infect Dis. 2015 Sep;83(1):53-5. doi: 10.1016/j.diagmicrobio.2015.04.012. Epub 2015 May 1.

PMID:
26003469
44.

Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.

Lo DK, Hurley MN, Muhlebach MS, Smyth AR.

Cochrane Database Syst Rev. 2015 Feb 24;(2):CD009650. doi: 10.1002/14651858.CD009650.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Jul 21;7:CD009650.

PMID:
25927091
45.

Multicenter Observational Study on Factors and Outcomes Associated with Various Methicillin-Resistant Staphylococcus aureus Types in Children with Cystic Fibrosis.

Muhlebach MS, Heltshe SL, Popowitch EB, Miller MB, Thompson V, Kloster M, Ferkol T, Hoover WC, Schechter MS, Saiman L; STAR-CF Study Team.

Ann Am Thorac Soc. 2015 Jun;12(6):864-71. doi: 10.1513/AnnalsATS.201412-596OC.

46.

High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus.

Scheuplein VA, Seifried J, Malczyk AH, Miller L, Höcker L, Vergara-Alert J, Dolnik O, Zielecki F, Becker B, Spreitzer I, König R, Becker S, Waibler Z, Mühlebach MD.

J Virol. 2015 Apr;89(7):3859-69. doi: 10.1128/JVI.03607-14. Epub 2015 Jan 21.

47.

Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from cystic fibrosis (CF) and non-CF patients.

Sherrard LJ, Schaible B, Graham KA, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, Muhlebach MS, Gilpin DF, Schneiders T, Elborn JS, Tunney MM.

J Antimicrob Chemother. 2014 Oct;69(10):2690-8. doi: 10.1093/jac/dku192. Epub 2014 Jun 10. Erratum in: J Antimicrob Chemother. 2018 Nov 1;73(11):3218.

48.

A single amino acid substitution in the measles virus F₂ protein reciprocally modulates membrane fusion activity in pathogenic and oncolytic strains.

Heidmeier S, Hanauer JR, Friedrich K, Prüfer S, Schneider IC, Buchholz CJ, Cichutek K, Mühlebach MD.

Virus Res. 2014 Feb 13;180:43-8. doi: 10.1016/j.virusres.2013.12.016. Epub 2013 Dec 22.

PMID:
24368277
49.

Inter-α-inhibitor blocks epithelial sodium channel activation and decreases nasal potential differences in ΔF508 mice.

Lazrak A, Jurkuvenaite A, Ness EC, Zhang S, Woodworth BA, Muhlebach MS, Stober VP, Lim YP, Garantziotis S, Matalon S.

Am J Respir Cell Mol Biol. 2014 May;50(5):953-62. doi: 10.1165/rcmb.2013-0215OC.

50.

Serum metabolomics indicate altered cellular energy metabolism in children with cystic fibrosis.

Joseloff E, Sha W, Bell SC, Wetmore DR, Lawton KA, Milburn MV, Ryals JA, Guo L, Muhlebach MS.

Pediatr Pulmonol. 2014 May;49(5):463-72. doi: 10.1002/ppul.22859. Epub 2013 Jul 12.

PMID:
23847148

Supplemental Content

Loading ...
Support Center